ADRB3 and peripheral arterial disease: Because of promising preclinical outcomes, authors proceeded with a clinical trial named STAR-PAD (stimulating β3-AR for peripheral artery disease) with mirabegron as intervention (50 mg/day orally) in patients suffering from intermittent claudication [138].